Abstract 978P
Background
The optimal treatment (Tx) strategy for aHCC pts who have progressed on frontline A/B is undefined. We evaluated 2nd line Tx patterns and clinical outcomes of aHCC pts following progression on A/B to identify factors associated with post-progression survival (PPS).
Methods
Real world patient data were retrieved from an international HCC database. PPS was from first radiographic progression on A/B to death. Kaplan-Meier median survivals and 95%CI were compared with univariate Cox-regression analysis. Univariate (UVA) and multivariate (MVA) Cox-regression analyses assessed the impact of baseline clinical factors on PPS.
Results
We identified 406 pts alive with progression on A/B. 220 continued active systemic Tx: 203 received 1 further line, 155 with tyrosine kinase inhibitors (TKIs), 45 with immunotherapy, and the remainder had missing data. Median duration of 2nd line Tx was 2.2 months (mo) (IO: 2.3 mo, TKI; 2.1). Compared to pts who received best supportive care (BSC; n=186), pts on active Tx were younger, Child Pugh class (CP) A , ECOG <2 when A/B stopped, had viral etiology, no extrahepatic disease, and had disease control during A/B. Median follow-up from A/B progression was 7.5 mo (95%CI 6.3-8.6). mPPS for all pts was 6.0 mo (95%CI 5.2-7.2). Continued active Tx was associated with prolonged mPPS compared to BSC (9.7 vs 2.0 mo; HR: 0.30; 95%CI 0.2-0.4, p<0.001). mPPS was longer with IO (11.8 mo; 95%C: 6.4-NA) than with TKIs (8.1 mo; 95%CI 6.3-10.4) or BSC (2.0 mos ;95%CI 1.5-2.9). Male sex, ECOG ≥2 at time of A/B interruption, CP B/C, portal vein tumor thrombosis (PVTT), and primary progression on A/B were associated with increased risk of death in UVA. In MVA, PVTT, ECOG ≥2 and BSC independently predicted poor PPS. Active tx was associated with longer mPPS (8.6 mo, 95%CI 6.3-13.0 vs 2.5, 95%CI 2.1-4.4; HR:0.40, 95%CI 0.28-0.58) after performing propensity score matching for confounding factors (ECOG at A/B stop, PVTT, CPS, DCR during A/B).
Conclusions
In addition to known disease related factors, continuation of systemic Tx instead of BSC following progression on A/B is independently associated with improved PPS in pts with aHCC. mPPS was nearly 1 year with IO-based Tx, suggesting a potential role for IO beyond progression after A/B.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Incyte, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD, Zymeworks; Financial Interests, Institutional, Funding: Ipsen. A. Vogel: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Böhringer Mannheim, EISAI, Incyte, Ipsen, Janssen, MSD, PierreFabre, Roche, Servier, Sirtex, Tyra, Tahio; Financial Interests, Personal, Invited Speaker: BMS, Eisai, Incyte, Ipsen, Lilly, MSD, Roche; Financial Interests, Personal, Steering Committee Member: Roche, MSD, BeiGene, Jiangsu Hengrui Medicines.. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, MSD; Financial Interests, Institutional, Research Grant: Otsuka, Sumitomo Dainippon Pharma, EA Pharma, Taiho, Eisai, AbbVie, Gilead Sciences, Takeda, GE Healthcare, Chugai. S. Ulahannan: Financial Interests, Personal, Advisory Board: array, incyte, bayer, syros, eisai, AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, adlai nortye, arqule, atreca, BI, BMS, Celgene, Ciclomed LLC, Erasca, Evelo Biosciences, Exelexis, G1 Therapeutics, GSK, IGM biosciences, Incyte, isofol, Klus pharma, Macrogenics, merck, Mersana, Oncomed, Pfizer, regeneron, Revolution Medicines, Synermore Biologics, Takeda, Tarveda Therapeutics, Tesaro, Tempest, Vigeo, Tvardi, hutch med. D.J. Pinato: Financial Interests, Personal, Advisory Board: Mina Therapeutics, EISAI, Exact Sciences, MURSLA, H3B, DaVolterra, AstraZeneca, Bayer Healthcare; Financial Interests, Personal, Invited Speaker: BMS, IPSEN, Roche; Financial Interests, Personal, Other, Editor in Chief role: Wiley; Financial Interests, Institutional, Research Grant: BMS, MSD; Non-Financial Interests, Principal Investigator: Incyte, H3B, Starpharma, Roche, Ribon Therapeutics, Turning Point Therapeutics, Apollomics; Non-Financial Interests, Other, Charity Trustee: Cancer Treatment and Research Trust. All other authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18